Dr. Kabita Patel, former Obama White House policy director, explained why the rise in Covid cases in the UK could be a compelling argument for booster shots.
“What’s happening is … this is a real-world experiment where AstraZeneca’s effectiveness is decreasing, and they’re not deploying boosters,” Patel told CNBC’s “Shepard Smith” Tuesday night. In an interview with “News”. “It’s a booster argument, and it’s very compelling.”
The UK’s initial vaccination rollout began in December 2020 and was one of the world’s first vaccinations. However, it is now believed that this contributes to the high case rate, with increasing data showing that the immunity of vaccinated people weakens after about 6 months.
The spread of more infectious deltacovid mutants in spring and summer is also thought to be a factor in reducing the effectiveness of the vaccine.
In September, the UK began offering booster shots to people aged 50 and over, medical workers and those with underlying health conditions. People who have received a second dose at least 6 months ago will have to come first. Currently, around 6.5 million people in the UK are eligible for boosters, and data show that the NHS has performed around 3.6 million booster shots to date.
Patel told host Shepard Smith that he was also on the lookout for Covid strains potentially contributing to the UK, which has one of the worst daily infection rates in the world.
“We are monitoring some sub-strains of the Delta strain. This is a very typical example of the increasing proportion in the UK… it may be more contagious than Delta. Yes, that makes it easier to get infected. It is even more contagious than Delta. ”
In the United States, The New York Times reported that the Food and Drug Administration has approved Johnson & Johnson and Modana boosters and will allow mix-and-match shots this week.
Source link UK Covid cases surge could be a “concrete discussion of a booster”